Edgewise Therapeutics CBO sells $223k in shares for tax obligations

On August 12, 2026, Behrad Derakhshan, Chief Business Officer at Edgewise Therapeutics, Inc., sold approximately 5,100 shares of the company's common stock, totaling around $223,424. The trades, known as "sell-to-cover" transactions, were made to satisfy tax obligations associated with the vesting of restricted stock units. The shares traded at prices between $43.29 and $44.54, nearly reaching Edgewise Therapeutics' 52-week high of $48.40.

On the same day, Derakhshan also purchased 13,281 shares of the company's common stock through the same vesting process. Additionally, he received 50,000 new restricted stock units and options to purchase 100,000 shares, which will vest over time. According to InvestingPro analysis, the stock is currently deemed overvalued. Edgewise Therapeutics recently sold its muscular dystrophy business to Servier for $2.65 billion, including an upfront payment and potential milestone payments.

Analysts have given mixed coverage, with Oppenheimer and Guggenheim setting price targets of $51 and raising their target to $51 from $41, respectively. RBC Capital increased its price target to $59.